U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 14 results

Status:
US Approved Rx (2019)
First approved in 1979

Class (Stereo):
CHEMICAL (ABSOLUTE)



Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar ...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (1995)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:


The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour activity. ...
Status:
US Approved Rx (1987)
First approved in 1961

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:


Vinblastine is a Vinca alkaloid obtained from the Madagascar periwinkle plant. Vinca alkaloids were found out in the 1950's by Canadian scientists, Robert Noble and Charles Beer for the first time. Medicinal applications of this plant lead to the mon...
Status:
US Approved Rx (2019)
First approved in 1979

Class (Stereo):
CHEMICAL (ABSOLUTE)



Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar ...
Status:
US Approved Rx (2019)
First approved in 1979

Class (Stereo):
CHEMICAL (ABSOLUTE)



Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar ...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

Showing 1 - 10 of 14 results